AU647859B2 - Anti-atherosclerotic aryl compounds - Google Patents

Anti-atherosclerotic aryl compounds

Info

Publication number
AU647859B2
AU647859B2 AU90560/91A AU9056091A AU647859B2 AU 647859 B2 AU647859 B2 AU 647859B2 AU 90560/91 A AU90560/91 A AU 90560/91A AU 9056091 A AU9056091 A AU 9056091A AU 647859 B2 AU647859 B2 AU 647859B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
formula
atoms
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU90560/91A
Other languages
English (en)
Other versions
AU9056091A (en
Inventor
James Mood Chapman
Karl Witold Franzmann
Roy Lee Hawke
Kevin Julian O'connor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Original Assignee
Wellcome Foundation Ltd
University of South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd, University of South Carolina filed Critical Wellcome Foundation Ltd
Publication of AU9056091A publication Critical patent/AU9056091A/en
Application granted granted Critical
Publication of AU647859B2 publication Critical patent/AU647859B2/en
Assigned to UNIVERSITY OF SOUTH CAROLINA reassignment UNIVERSITY OF SOUTH CAROLINA Alteration of Name(s) in Register under S187 Assignors: UNIVERSITY OF SOUTH CAROLINA, WELLCOME FOUNDATION LIMITED, THE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU90560/91A 1990-12-12 1991-12-11 Anti-atherosclerotic aryl compounds Ceased AU647859B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9027023 1990-12-12
GB909027023A GB9027023D0 (en) 1990-12-12 1990-12-12 Anti-atherosclerotic aryl compounds
PCT/GB1991/002195 WO1992010468A1 (en) 1990-12-12 1991-12-11 Anti-atherosclerotic aryl compounds

Publications (2)

Publication Number Publication Date
AU9056091A AU9056091A (en) 1992-07-08
AU647859B2 true AU647859B2 (en) 1994-03-31

Family

ID=10686924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU90560/91A Ceased AU647859B2 (en) 1990-12-12 1991-12-11 Anti-atherosclerotic aryl compounds

Country Status (16)

Country Link
US (1) US5658944A (Direct)
EP (1) EP0639178B1 (Direct)
JP (1) JP2951402B2 (Direct)
KR (1) KR930703246A (Direct)
AT (1) ATE157651T1 (Direct)
AU (1) AU647859B2 (Direct)
CA (1) CA2098122C (Direct)
DE (1) DE69127556D1 (Direct)
GB (1) GB9027023D0 (Direct)
HU (1) HUT64514A (Direct)
IE (1) IE914304A1 (Direct)
IL (1) IL100331A (Direct)
NZ (1) NZ240935A (Direct)
TW (1) TW275065B (Direct)
WO (1) WO1992010468A1 (Direct)
ZA (1) ZA919773B (Direct)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
SE9401353D0 (sv) * 1994-04-21 1994-04-21 Pharmacia Ab Novel antitumour compounds with antimitotic activity
AR002945A1 (es) * 1994-11-15 1998-05-27 Bayer Corp Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz, composicion que los contiene, y metodos para la preparacion de dichos compuestos
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5866609A (en) * 1996-08-09 1999-02-02 Ss Pharmaceutical Co., Ltd. Substituted vinylurea derivatives and medicine containing the same
NZ515284A (en) * 1999-04-28 2004-12-24 Dr Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
WO2002014291A1 (fr) 2000-08-11 2002-02-21 Nippon Chemiphar Co.,Ltd. ACTIVATEURS DE PPAR$G(d)
JPWO2002046176A1 (ja) * 2000-12-05 2004-04-08 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体の活性化剤
WO2002064549A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
WO2002064130A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
US6548538B2 (en) 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
US20030191144A1 (en) * 2001-06-12 2003-10-09 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
JP2005501817A (ja) * 2001-06-12 2005-01-20 アクティブ パス ファーマシューティカルズ， インコーポレイテッド β−アミロイド産生を調節する化合物、組成物および方法
JP4421895B2 (ja) 2001-08-10 2010-02-24 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
CN1293076C (zh) 2001-10-12 2007-01-03 日本化学医药株式会社 过氧化物酶体增殖剂应答性受体δ的活化剂
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
AU2003241579B9 (en) 2002-06-19 2009-07-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
ES2325783T3 (es) 2002-10-21 2009-09-17 Janssen Pharmaceutica Nv Tetralina e indano sustituidos y su utilizacion.
DK1567493T3 (da) * 2002-11-26 2009-06-08 Pfizer Prod Inc Phenyl-substituerede piperidin-forbindelser til anvendelse som PPAR-aktivatorer
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
MXPA06014495A (es) 2004-06-17 2007-03-01 Cytokinetics Inc Compuestos, composiciones y metodos.
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP1962852B1 (en) 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
CN101466687B (zh) 2006-04-18 2012-04-11 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
KR101710340B1 (ko) 2008-04-15 2017-02-27 닛뽕 케미파 가부시키가이샤 퍼옥시좀 증식제 활성화 수용체의 활성화제
US9187411B2 (en) 2012-01-10 2015-11-17 Eli Lilly And Company Leukotriene B4 antagonist compound
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397868A (en) * 1982-01-26 1983-08-09 American Cyanamid Company Method of treating atherosclerosis with trisubstituted ureas
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
AU638950B2 (en) * 1988-11-21 1993-07-15 Wellcome Foundation Limited, The Anti-antherosclerotic diaryl compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614045A1 (de) * 1976-04-01 1977-10-06 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeuren und verfahren zur herstellung derselben
US4387106A (en) * 1982-01-26 1983-06-07 American Cyanamid Company Method of treating atherosclerosis with di(aralkyl)ureas and di(aralkyl)thioureas
AU616674B2 (en) * 1987-06-15 1991-11-07 Iraj Lalezari Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation
US4921997A (en) * 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397868A (en) * 1982-01-26 1983-08-09 American Cyanamid Company Method of treating atherosclerosis with trisubstituted ureas
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
AU638950B2 (en) * 1988-11-21 1993-07-15 Wellcome Foundation Limited, The Anti-antherosclerotic diaryl compounds

Also Published As

Publication number Publication date
IE914304A1 (en) 1992-06-17
JPH06507151A (ja) 1994-08-11
KR930703246A (ko) 1993-11-29
ZA919773B (en) 1993-06-11
US5658944A (en) 1997-08-19
CA2098122C (en) 2003-09-23
TW275065B (Direct) 1996-05-01
IL100331A (en) 1996-09-12
WO1992010468A1 (en) 1992-06-25
CA2098122A1 (en) 1992-06-13
EP0639178B1 (en) 1997-09-03
HU9301709D0 (en) 1993-09-28
DE69127556D1 (de) 1997-10-09
EP0639178A1 (en) 1995-02-22
HUT64514A (en) 1994-01-28
NZ240935A (en) 1994-11-25
GB9027023D0 (en) 1991-01-30
ATE157651T1 (de) 1997-09-15
IL100331A0 (en) 1992-09-06
JP2951402B2 (ja) 1999-09-20
AU9056091A (en) 1992-07-08

Similar Documents

Publication Publication Date Title
AU647859B2 (en) Anti-atherosclerotic aryl compounds
EP1446115B1 (en) Cyanoalkylamino derivatives as protease inhibitors
WO1991001306A1 (en) Oxoindole derivative
KR880000204B1 (ko) 설포닐 우레아 유도체
EA019882B1 (ru) Модуляторы рецептора простациклина (pgi2), пригодные для лечения связанных с ним расстройств
CN1246119A (zh) 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途
CN113226296A (zh) Ssao抑制剂及其用途
EA032314B1 (ru) Трициклические гетероциклические соединения, применимые в качестве ингибиторов tnf
PL154186B1 (en) Method for manufacturing arylic derivatives of the hydroxamic acid
EP3455212B1 (en) Inhibitors of protease-activated receptor-2
US4988682A (en) Myo-inositol analogs and method for their use
WO2016079669A1 (en) Labeled amino pyrimidine derivatives
US5422373A (en) Anti-atherosclerotic aryl compounds
FR2534582A1 (fr) Nouveaux derives de benzofuranne et de benzothiophene, utiles comme agents anti-hyperuricemie et anti-hypertension, et leur procede de fabrication
EP2324015B1 (fr) Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
FR2483232A1 (fr) Nouveaux agents anti-rhinovirus et leur procede de preparation
US5053399A (en) Myo-inositol analogs and methods for their use
CN103193695B (zh) 3-苯基-3-吡咯基戊烷类衍生物及其医药用途
FR2763847A1 (fr) Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
LU83827A1 (fr) Nouveaux composes heterocycliques azotes anti-inflammatoires et immunoregulateurs et composition pharmaceutique les contenant
BE1000783A3 (fr) Derives du 1,3-dioxolanne et du 1,3-dioxanne et leur utilisation comme medicaments.
EP0189080A2 (en) (1,2,4-Oxadiazol-3-YL)-arylmethanones, a process for their preparation and their use as medicaments
KR880001754B1 (ko) 에테르류 화합물의 제조방법
WO2012104538A1 (fr) Nouveaux dérivés de 1, 5 - dihydropyrrol - 2 - one utiles pour le traitement paludisme ou d'autres maladies parasitaires et fongiques
WO2010109150A1 (fr) Derives de 3-alcoxy-4,5-diarylthiophene-2-carboxamide, leur preparation et leur application en therapeutique